QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
CSIRO announces 300+ job cuts as part of restructure
CSIRO will need to reduce roles in its Research Units by 300–350 full-time equivalent staff...
Synchron raises $305m to advance brain–computer interfaces
Synchron's Stentrode BCI platform is billed as the world's first endovascular...
Air quality expert wins 2025 PM's Prize for Science
Distinguished Professor Lidia Morawska's work in the study of air quality provided vital...
